Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026)

Arvinas' (ARVN) quarterly Non-Current Deffered Revenue came in at $138.2 million in Q1 2026, up 16.72% year-on-year from $118.4 million in Q1 2025, and up 2.9% quarter-over-quarter from $134.3 million in Q4 2025.

Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends

Arvinas' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $138.2 million for Q1 2026.

  • On a quarterly basis, Non-Current Deffered Revenue rose 16.72% year-over-year to $138.2 million in Q1 2026; TTM through Mar 2026 was $138.2 million, a 16.72% increase from a year earlier, with the FY2025 full-year figure at $134.3 million, down 54.01% from the prior year.
  • Non-Current Deffered Revenue climbed to $138.2 million in Q1 2026 per ARVN's latest filing, from $134.3 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $521.9 million in Q1 2022 and bottomed at $118.4 million in Q1 2025.
  • The 5-year median for Non-Current Deffered Revenue is $310.5 million (2023), against an average of $304.9 million.
  • Across the five-year window, Non-Current Deffered Revenue jumped 3221.04% in 2022 and tumbled 67.2% in 2025, its largest moves.
  • Year by year, Non-Current Deffered Revenue stood at $405.1 million in 2022, then decreased by 4.67% to $386.2 million in 2023, then retreated by 24.39% to $292.0 million in 2024, then tumbled by 54.01% to $134.3 million in 2025, then rose by 2.9% to $138.2 million in 2026.
  • Per Business Quant, the three latest ARVN Non-Current Deffered Revenue figures stand at $138.2 million (Q1 2026), $134.3 million (Q4 2025), and $127.4 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arvinas 519.68 Mn -95.22 Mn - 138.20 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 138.20 Mn
Dec 31, 2025 134.30 Mn
Sep 30, 2025 127.40 Mn
Jun 30, 2025 134.10 Mn
Mar 31, 2025 118.40 Mn
Dec 31, 2024 292.00 Mn
Sep 30, 2024 304.50 Mn
Jun 30, 2024 331.30 Mn
Mar 31, 2024 361.00 Mn
Dec 31, 2023 386.20 Mn
Sep 30, 2023 281.90 Mn
Jun 30, 2023 310.50 Mn
Mar 31, 2023 378.90 Mn
Dec 31, 2022 405.10 Mn
Sep 30, 2022 464.60 Mn
Jun 30, 2022 493.60 Mn
Mar 31, 2022 521.90 Mn
Dec 31, 2021 534.30 Mn
Sep 30, 2021 600.43 Mn
Jun 30, 2021 14.86 Mn